05:55 PM EDT, 09/05/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) and Shilpa Medicare said late Thursday the US Food and Drug Administration has approved Boruzu, the first ready-to-use version of the bortezomib injection for subcutaneous administration.

Boruzu is used to treat multiple myeloma and mantle cell lymphoma.

Shilpa developed the molecule, while Amneal will produce and commercialize the product, the companies said.

Boruzu is expected to launch with a unique J-code in Q2 2025.

Amneal shares were down almost 2% in after-hours activity.

Price: 8.30, Change: -0.15, Percent Change: -1.78